Yale Jen
Stock Analyst at Laidlaw
(0.23)
# 4,470
Out of 4,639 analysts
75
Total ratings
27.1%
Success rate
-8.9%
Average return
Main Sectors:
Stocks Rated by Yale Jen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NCEL NewcelX | Initiated Coverage: Buy | $23 | $3.19 | +621.00% | 2 | Jul 13, 2026 | |
| KZIA Kazia Therapeutics | Initiated Coverage: Buy | $25 | $13.88 | +80.12% | 1 | Apr 15, 2026 | |
| FEMY Femasys | Initiated Coverage: Buy | $130 | $2.35 | +5,431.91% | 1 | Nov 20, 2025 | |
| NSRX Nasus Pharma | Initiated Coverage: Buy | $22 | $3.31 | +564.65% | 1 | Sep 29, 2025 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $110 | $33.80 | +225.44% | 3 | Aug 20, 2025 | |
| SNTI Senti Biosciences Holdings | Initiated Coverage: Buy | $5 | $0.3573 | n/a | 1 | Jun 6, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterated: Buy | $11 | $1.51 | n/a | 4 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiated Coverage: Buy | $19 | $19.41 | n/a | 1 | Mar 17, 2025 | |
| LFWD Lifeward | Initiated Coverage: Buy | $10 | $7.57 | n/a | 1 | Feb 10, 2025 | |
| XAIR Beyond Air | Maintained: Buy | $16 → $100 | $5.84 | n/a | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 | $55.42 | n/a | 8 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 → $20 | $2.31 | n/a | 5 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $126.81 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.9012 | n/a | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $7.52 | n/a | 6 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $13.05 | n/a | 3 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.5 → $225 | $1.05 | n/a | 3 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $25 | $0.0001 | n/a | 5 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $0.1588 | n/a | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $5.20 | n/a | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0082 | n/a | 2 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $3.56 | n/a | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.97 | n/a | 3 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 → $10 | $0.0127 | n/a | 2 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 → $20 | $0.534 | n/a | 3 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.73 | $9.91 | n/a | 1 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.541 | n/a | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $8.5 | $1.39 | n/a | 2 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0025 | n/a | 2 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $0.7954 | n/a | 1 | May 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 → $90 | $3.83 | n/a | 2 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $5.57 | n/a | 1 | Sep 27, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $3.5 | $3.88 | n/a | 1 | Sep 16, 2014 |
NewcelX
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $3.19
Upside: +621.00%
Kazia Therapeutics
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $13.88
Upside: +80.12%
Femasys
Nov 20, 2025
Initiated Coverage: Buy
Price Target: $130
Current: $2.35
Upside: +5,431.91%
Nasus Pharma
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $22
Current: $3.31
Upside: +564.65%
Viking Therapeutics
Aug 20, 2025
Reiterated: Buy
Price Target: $110
Current: $33.80
Upside: +225.44%
Senti Biosciences Holdings
Jun 6, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $0.3573
Upside: n/a
Aldeyra Therapeutics
Apr 4, 2025
Reiterated: Buy
Price Target: $11
Current: $1.51
Upside: n/a
Nuvectis Pharma
Mar 17, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $19.41
Upside: n/a
Lifeward
Feb 10, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $7.57
Upside: n/a
Beyond Air
Nov 12, 2024
Maintained: Buy
Price Target: $16 → $100
Current: $5.84
Upside: n/a
Oct 8, 2024
Reiterated: Buy
Price Target: $68
Current: $55.42
Upside: n/a
Sep 27, 2024
Reiterated: Buy
Price Target: $22 → $20
Current: $2.31
Upside: n/a
Jul 29, 2024
Initiated Coverage: Buy
Price Target: $48
Current: $126.81
Upside: n/a
Jul 23, 2024
Downgraded: Hold
Price Target: n/a
Current: $0.9012
Upside: n/a
Jul 2, 2024
Reiterated: Buy
Price Target: $79
Current: $7.52
Upside: n/a
Jun 26, 2024
Reiterated: Buy
Price Target: $50
Current: $13.05
Upside: n/a
Jun 14, 2024
Reiterated: Buy
Price Target: $7.5 → $225
Current: $1.05
Upside: n/a
Jun 12, 2024
Maintained: Buy
Price Target: $11 → $25
Current: $0.0001
Upside: n/a
May 28, 2024
Initiated Coverage: Buy
Price Target: $25
Current: $0.1588
Upside: n/a
Dec 22, 2023
Downgraded: Hold
Price Target: n/a
Current: $5.20
Upside: n/a
Dec 12, 2023
Downgraded: Hold
Price Target: n/a
Current: $0.0082
Upside: n/a
Aug 28, 2023
Initiated Coverage: Buy
Price Target: $10
Current: $3.56
Upside: n/a
Aug 15, 2023
Downgraded: Hold
Price Target: n/a
Current: $1.97
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: $30 → $10
Current: $0.0127
Upside: n/a
Mar 14, 2022
Reiterated: Buy
Price Target: $18 → $20
Current: $0.534
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: $5.73
Current: $9.91
Upside: n/a
Aug 24, 2020
Downgraded: Hold
Price Target: n/a
Current: $0.541
Upside: n/a
Jul 31, 2020
Maintained: Buy
Price Target: $6 → $8.5
Current: $1.39
Upside: n/a
Aug 9, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.0025
Upside: n/a
May 20, 2019
Initiated Coverage: Buy
Price Target: $10
Current: $0.7954
Upside: n/a
Nov 15, 2018
Maintained: Buy
Price Target: $4 → $90
Current: $3.83
Upside: n/a
Sep 27, 2016
Maintained: Hold
Price Target: n/a
Current: $5.57
Upside: n/a
Sep 16, 2014
Initiated Coverage: Buy
Price Target: $3.5
Current: $3.88
Upside: n/a